Mobile Phlebotomy Service
Blood draws on wheels for labs, trials, and homebound patients
Bottom line
Accessible entry point; validate local supply before buying.
Mobile phlebotomy companies send certified phlebotomists to homes, senior living facilities, employers, and clinical trial participants to collect blood and specimen samples. The surprising angle is that this tiny, boring service is piggybacking on the rise of home healthcare and decentralized clinical trials. Quest Diagnostics notes mobile blood draws can improve clinical trial retention by 25% and cut turnaround time by about 3 days, which makes the service far more strategic than a simple house call.
How It Works
You contract with labs, physician groups, insurers, home health agencies, or research organizations that need specimen collection outside a clinic. Revenue comes from per-visit draw fees, mileage, STAT surcharges, employer wellness events, and recurring route work in senior facilities. Once dispatch and lab handoff are dialed in, the business scales by adding phlebotomists rather than expensive equipment.
BizBite verdict
Watch / verify
Mobile Phlebotomy Service maps to the Mobile Phlebotomy Service model. The category can work for acquisition buyers, but the right answer depends on source freshness, verified economics, and the specific red flags below.
Why it may work
- +Attractive 34% estimated margin profile
- +SBA dataset shows 3 recent comparable loans
- +5 clear operating upside levers identified
Be careful
- !Source link status has not been verified yet
- !No last-checked date yet
Category operating model
Mobile Phlebotomy Service
Revenue drivers
- • Specimen-collection visits sold to labs, physician groups, home-health agencies, trials, employers, and cash-pay consumers
- • Route density by ZIP code, senior facility, employer event, and recurring lab contract
- • Per-visit fees, mileage, STAT surcharges, after-hours fees, specimen handling complexity, and cancellation terms
- • Phlebotomist availability, credentialing, patient experience, and dispatch reliability
- • Clinical trial and specialty testing work where home collection improves retention and turnaround
Key risks
- • Travel inefficiency can turn good visit fees into weak route economics
- • A few lab/referral partners can control volume
- • Specimen rejection, labeling errors, or chain-of-custody mistakes can end contracts
- • Worker classification and credentialing issues can create healthcare and labor risk
- • Consumer cash-pay demand is less durable than recurring B2B routes
What you need to believe
- Route density and B2B contracts make the economics recurring rather than gig-work medicine
- Specimen integrity is documented well enough for labs to trust a new owner
- The phlebotomist bench can expand without collapsing patient experience
- Mileage, cancellations, and STAT work are priced rather than absorbed
- Referral partners will transfer after the seller exits
Unit economics
How one unit makes money
Modeled per one local dispatch route with 3-5 phlebotomists serving homebound, senior-facility, lab, employer, and trial draws. Every line shows its arithmetic — rebuild any number yourself.
Revenue build-up
| Line | Low | Base | High |
|---|---|---|---|
| Recurring lab, physician, senior-facility, and home-health routes15 recurring accounts × ~26 billable draws/month × $40 average fee × 12 months | $60K | $188K | $500K |
| One-off home draws, STAT visits, mileage, and cash-pay requests1,600 annual one-off visits × ~$60 blended draw/mileage/STAT revenue | $40K | $96K | $250K |
| Clinical trial, employer wellness, and specialty collection projects35 event/project days × ~$1,900 average revenue from grouped participants or specialized handling | $20K | $67K | $150K |
Where it goes — cost structure
- Phlebotomist labor and payroll burden32–45%
The draw itself is quick; the paid time is driving, waiting, labeling, and patient handholding.
- Mileage, parking, vehicles, routing, and dispatch8–16%
A $55 draw thirty minutes off route is not the same product as six draws in one senior building.
- Supplies, PPE, specimen packaging, courier/cold-chain handling4–9%
Supply cost is small until specialty kits, redraws, and rejected specimens appear.
- Compliance, insurance, training, background checks, QA4–8%
Labs buy error-free chain-of-custody more than they buy needles.
- Sales, onboarding, software, admin, and bad debt6–10%
What actually swings the deal
- Draws per route-hour
+1 extra draw/day at $50 across 250 working days ≈ +$12.5K revenue per phlebotomist, with little extra overhead if on-route
- Average mileage per draw
cutting 5 miles from 3,000 annual visits at $0.67/mile equivalent saves about $10K before time savings
- Specimen rejection/redraw rate
a 3% redraw rate on 3,000 visits creates 90 unpaid return trips plus contract trust damage
- Top referral partner concentration
losing one 20% lab/referral partner on a $350K route removes $70K revenue immediately
Benchmarks to memorize
A phlebotomist doing 5-7 clean draws/day across 250 working days produces 1,250-1,750 visits/year. Past that, growth comes from tighter route clusters or another phlebotomist; accepting distant cash-pay draws is how the model quietly breaks.
Market analysis
Who owns these & where demand comes from
A young, fragmented healthcare logistics niche sitting between labs, home health, clinical trials, and patient convenience. SBA data is still thin — 13 tracked broad ambulatory-health acquisitions with a ~$388K median implied deal — which fits a market where many operators are local dispatch/service businesses, not scaled platforms.
Tailwinds
- ↗ Home healthcare and decentralized trial models legitimize specimen collection outside clinics
- ↗ An aging population increases demand for homebound draws
- ↗ Labs value reliable route partners that reduce no-shows and specimen failures
Headwinds
- ↘ Large labs can internalize routes in dense markets
- ↘ Low consumer draw fees can attract gig-like operators and price pressure
- ↘ Compliance errors, specimen rejections, and worker shortages can end contracts quickly
Demand drivers
- Homebound and senior patients who cannot easily visit patient service centers
- Decentralized clinical trials and specialty testing that need participants to stay enrolled
- Labs and physician groups trying to extend coverage without adding fixed sites
- Employer wellness and concierge/cash-pay healthcare where convenience is part of the product
Regulation
Rules vary by state and contract, but the practical diligence stack is phlebotomist credentialing, HIPAA, OSHA bloodborne-pathogen training, specimen labeling/transport, CLIA-lab handoff requirements, and liability coverage.
Who you bid against
Buyers include healthcare service operators, labs, home-health companies, clinical-trial service vendors, and searchers attracted to low capex. Strategic buyers pay for contracted route density and rejection-rate proof, not a list of cash-pay calls.
Competitive advantage
What protects the good ones
- strongRoute density
The same $50 draw is attractive inside a senior building and terrible thirty minutes off route.
- strongLab/referral relationships
Labs and clinics keep vendors who avoid redraws, show up on time, and make specimen handoff boring.
- moderateCompliance and chain-of-custody process
Specimen integrity is the invisible product; one labeling pattern can wreck a contract.
- moderatePhlebotomist bench and patient experience
Patients remember bad sticks and missed windows; referral sources remember complaints.
Who wins — and who loses
The winner batches draws by building and ZIP code, documents specimen integrity, prices mileage/STAT work, and owns recurring lab/facility relationships. The loser takes every one-off consumer draw, pays windshield time like charity, and finds out that a rejected tube costs more than the original visit.
How this niche degrades
- ↘ Large labs can pull dense routes in-house when volume justifies it
- ↘ Reimbursement/contract changes can push more cost onto the mobile vendor
- ↘ Specimen error or privacy incident can terminate contracts immediately
- ↘ Gig-style low-price entrants can pressure cash-pay one-offs, though they struggle with B2B compliance
Early. The category is attractive to healthcare logistics and trial-support buyers, but most local routes are too small or under-documented. Clean route data and contracted referral partners are the unlock.
SBA 7(a) data
Real acquisitions in this category
Change-of-ownership loans · NAICS 621999 · All Other Miscellaneous Ambulatory Health Care Services
Deal size distribution
Financing profile
Recent comparable deals
| Closed | State | Loan | Implied deal |
|---|---|---|---|
| Dec 2024 | WI | $150K | $177K |
| Dec 2024 | WI | $712K | $838K |
| Jun 2024 | MI | $852K | $1.0M |
| Apr 2024 | MN | $250K | $294K |
| Apr 2024 | MN | $1.4M | $1.6M |
| Jun 2023 | AZ | $435K | $512K |
| Feb 2023 | AL | $295K | $347K |
| Sep 2022 | WA | $646K | $760K |
| Sep 2021 | MN | $59K | $69K |
| Jun 2021 | CA | $250K | $294K |
Source: SBA 7(a) FOIA dataset, filtered to acquisitions (loans where business age is "Change of Ownership"). Implied deal size assumes an 85% loan-to-purchase ratio, a common SBA change-of-ownership structure. Charge-off rate shown only when 10+ loans have resolved (paid in full or charged off). Interest rates reflect last 24 months only. Actual deal values vary with equity injections, seller financing, and working capital terms.
Valuation framework
How these actually get priced
Valued on SDE with a sharp split between recurring B2B route revenue and volatile one-off consumer demand. Premiums go to assignable lab/facility contracts, low rejection rates, route density, and a stable phlebotomist bench; discounts apply to seller-referral dependency and unpriced travel.
What moves the multiple
- ▲ PremiumRecurring lab/facility/trial contracts
Contracted route volume is more valuable than cash-pay one-offs.
- ▲ PremiumRoute density and rejection-rate proof
These prove the service can scale without destroying patient trust or margin.
- ▼ DiscountReferral concentration
A single lab relationship can disappear or internalize the route.
- ▼ DiscountWeak compliance/specimen controls
Redraws, privacy issues, and chain-of-custody failures directly threaten contracts.
Worked example
At the BizBite midpoint, $350K revenue × 34% SDE margin = ~$119K SDE. Applying the 2.0x-4.0x range gives roughly $238K-$476K of value. A buyer can pay toward the high end for contracted senior-facility/lab routes with low redraws; a seller-dependent cash-pay house-call book belongs near the bottom.
Common buyer mistakes
- ✕ Underwriting visit count without route-hour economics
- ✕ Treating specimen rejection as a clinical nuisance instead of lost gross margin and contract risk
- ✕ Buying referral relationships without assignable agreements or partner calls
- ✕ Ignoring phlebotomist turnover and credentialing files because capex is low
Deal Calculator
Priced off $119K SDE — can this deal service its own debt?
SDE = revenue × margin estimate for this niche; it includes owner compensation, so budget your salary out of cash flow. Excludes working-capital injection, capex reserves, and taxes. Actual SBA terms vary by lender and borrower.
Due diligence checklist
Before you sign anything
- 01
Rebuild 24 months of visits by ZIP, source, fee, mileage, phlebotomist, wait time, cancellation, rejection/redraw, and gross margin.
This verifies route density, mileage, rejection, and unit economics.
Red flagHigh visit count comes from scattered low-fee draws with hidden windshield time. - 02
Review all lab, clinic, facility, employer, and trial agreements for pricing, mileage, STAT, cancellation, assignment, and termination.
Recurring revenue only matters if contracts transfer and price the actual service burden.
Red flagTop referral partners are informal or can terminate immediately. - 03
Audit specimen handling: labeling, chain-of-custody, courier handoff, temperature controls, rejection logs, and incident reports.
Specimen integrity is the core quality metric.
Red flagNo tracked rejection rate or repeated redraws blamed on patients. - 04
Verify phlebotomist credentials, training, background checks, pay, productivity, turnover, and worker classification.
Labor supply and compliance drive the SDE bridge.
Red flagContractors are misclassified or the best phlebotomists are seller-loyal with no retention plan. - 05
Call top labs/facilities/trial sponsors about service reliability and transition risk.
Relationship transfer is the moat.
Red flagPartners say they call the seller personally when anything goes wrong. - 06
Map routes by day and simulate removing the least dense 20% of visits.
A route business often becomes more valuable by firing bad geography.
Red flagRevenue collapses if unprofitable outlier visits are removed.
Pros
- +Rides the home-health and decentralized-trial trend without owning a lab
- +Low startup cost compared with most healthcare businesses
- +Recurring B2B relationships can stabilize volume
- +A good dispatch network creates a real local moat
Cons
- -Credentialing, specimen handling, and compliance matter a lot
- -Travel inefficiency can destroy margins fast
- -Some contracts depend on a handful of referral partners
Best For
Operators with healthcare ops experience who can manage field staff, routing, and compliance without overcomplicating it
Operating Costs
Main costs are labor, mileage, scheduling software, supplies, liability insurance, and occasional courier or cold-chain logistics. Margins improve when you cluster recurring draws by geography and win institutional accounts instead of one-off consumer jobs.
Where to Buy
Market overview for mobile phlebotomy and home-based specimen collection
Evidence that mobile blood draws improve trial retention and turnaround
Marketplace where healthcare service businesses periodically appear
Buyer's Toolkit
Essential tools to get started
Some links may be affiliate links. We only recommend tools we'd use ourselves.
Ready to Buy? Start Here →
Largest business-for-sale marketplace in the US
SBA loans and business acquisition financing — get funded fast
ROBS financing — use retirement funds to buy a business tax-free
Bookkeeping for small business owners — hands-off financials
Some links may be affiliate links. We only recommend tools we'd use ourselves.
Get the full breakdown in your inbox
Weekly boring business breakdowns
One researched boring-business breakdown every week. Free.